
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 16, 2006**

PEREGRINE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State of other jurisdiction
of incorporation)

0-17085

(Commission File Number)

95-3698422

(IRS Employer
Identification No.)

14272 Franklin Avenue, Tustin, California 92780

(Address of Principal Executive Offices)

Registrant's telephone number, including area code: **(714) 508-6000**

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
 - Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 1.01. Entry Into a Material Definitive Agreement.

On June 16, 2006 (the “Effective Date”), the Registrant entered into a Common Stock Purchase Agreement (the “Agreement”) with Double U Master Fund LP, an institutional investor (the “Investor”), pursuant to which the Registrant is selling, and the Investor is purchasing, 9,285,714 shares of the Registrant’s common stock in exchange for aggregate proceeds of \$13 million. Pursuant to the Agreement, the funding of the purchase and sale will occur no later than the end of the month (the “Closing Date”). The shares of common stock are being issued from the Registrant’s shelf registration statement on Form S-3, File No. 333-132872. No commissions were paid, nor warrants issued, in connection with the transaction. After giving effect to this Agreement, the Company will have 188,702,218 shares of common stock outstanding.

Pursuant to the terms of the Agreement, the Registrant has agreed not to (i) file another shelf registration statement pursuant to Rule 415 of the Securities Act of 1933, as amended, for a period of one hundred eighty days following the Effective Date, nor (ii) without the prior written consent of the Investor, prior to January 2, 2007, enter into any subsequent or further offer or sale of securities (including common stock issued for services provided to the Company, but excluding common stock issued in strategic licensing transactions where the Company is either in-licensing new technologies or out-licensing of technologies) at a price or possible price below \$2.50 per share. In addition, subject to certain terms, and pursuant to the Agreement, the Registrant has granted to the Investor a right of first refusal to purchase any new securities that the Registrant may propose to issue prior to January 2, 2007. All of the foregoing restrictions shall terminate sooner in the event that the closing price of the Registrant’s common stock shall equal or exceed \$2.50 for a period of fifteen (15) consecutive trading days at any time commencing thirty (30) business days following June 16, 2006.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits. The following material is filed as an exhibit to this Current Report on Form 8-K:

Exhibit Number	Description
99.1	Press Release issued June 19, 2006
99.2	Common Stock Purchase Agreement between Registrant and Double U Master Fund LP dated June 16, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PEREGRINE PHARMACEUTICALS, INC.

Date: June 19, 2006

By: /s/ Paul Lytle

Paul Lytle
Chief Financial Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release issued June 19, 2006
99.2	Common Stock Purchase Agreement between Registrant and Double U Master Fund LP dated June 16, 2006



Investors

Betsy Brod
The Brod Group
(800) 987-8256
ir@peregrineinc.com

Media

Barbara Lindheim & Stephen Gendel
GendeLLindheim BioCom Partners
(212) 918-4650

Peregrine Pharmaceuticals Announces \$13 Million Equity Financing

Tustin, CA., June 19, 2006 -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for the treatment of cancer and serious viral infections, today announced that it has signed a definitive agreement for the sale of 9,285,714 shares of common stock to one institutional investor, The Double U Master Fund LP, in exchange for net proceeds of \$13,000,000. Pursuant to the agreement and subject to certain conditions, Peregrine Pharmaceuticals has agreed not to offer or sell its common stock in any private placements at a price below \$2.50 per share during the remainder of the calendar year.

The proceeds from this offering will be used to advance the company's lead clinical programs, including a Phase Ib repeat dose study of bavituximab for the treatment of hepatitis C virus infection that follows positive safety and initial efficacy results in a Phase Ia trial; a Phase I study of bavituximab for the treatment of solid tumor cancer and a Phase II/III study of Cotara® for the treatment of brain cancer. The company also intends to use part of the proceeds to accelerate the clinical progress of these lead drug candidates by adding additional clinical programs in the U.S. or abroad. In addition, the proceeds will be used to further fund preclinical programs that are assessing the potential utility of bavituximab for the treatment of influenza, including avian flu, as well as for HIV infection, cytomegalovirus and other lethal viruses.

The shares are being sold pursuant to the company's shelf registration statement on Form S-3 filed with the Securities and Exchange Commission and declared effective on April 12, 2006. There were no warrants issued or any commissions paid in conjunction with the transaction.

Double U Master Fund LP is an investor in a variety of PIPE and other private equity transactions in the U.S. and internationally. In 2005, it was rated among the top 25 institutional investors in PIPE transactions, ranked by number of transactions, as published by Sagient Research Systems.

About Peregrine

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical trials in cancer and HCV infection with its lead product candidates bavituximab (formerly Tarvacin) and Cotara®. The company recently reported that bavituximab demonstrated good safety and encouraging signs of anti-viral activity in a Phase I HCV study. Peregrine also has in-house manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement:

Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceutical's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that bavituximab's safety profile in a repeat dose trial or in a combination therapy trial will not be at the same safety level as was found in the phase 1a trial, the risk that the results of future trials will not correlate to the results from the phase 1a trial, and the risk that bavituximab will not be as well tolerated at ascending doses. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2005, and the quarterly report on Form 10-Q for the quarter ended January 31, 2006. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

PEREGRINE PHARMACEUTICALS, INC.

**COMMON STOCK
PURCHASE AGREEMENT**

**9,285,714 SHARES OF
COMMON STOCK**

June 16, 2006

COMMON STOCK PURCHASE AGREEMENT

This Common Stock Purchase Agreement (this "Agreement") is made and entered into as of June 16, 2006 (the "Effective Date"), by and between Peregrine Pharmaceuticals, Inc., a Delaware corporation (the "Company"), and Double U Master Fund LP (the "Investor").

RECITALS

WHEREAS, the Company has filed with the Securities and Exchange Commission ("SEC") a Shelf Registration Statement on Form S-3 No. 333-132872, which was declared effective by the SEC on April 12, 2006 (the "Form S-3").

WHEREAS, pursuant to the Form S-3, the Company may offer to the public from time to time up to 15,000,000 shares of common stock, par value \$0.001 per share (the "Common Stock").

WHEREAS, the Company desires to sell and issue to the Investor under the Form S-3 the sum of 9,285,714 shares of Common Stock, all in the manner described below.

NOW, THEREFORE, in consideration of the covenants, agreements and considerations herein contained, the Company and Investor agree as follows:

1. PURCHASE AND SALE OF SHARES

1.1 Purchase and Sale of Shares. Subject to the terms and conditions hereof, the Company hereby sells to the Investor, and the Investor hereby purchases from the Company, the sum of 9,285,714 shares of Common Stock (the "Shares"), in consideration for the Investor's payment on the Closing Date (as defined below) the Purchase Price (as defined below).

1.2 Purchase Price. As full consideration for the sale of the Shares to Investor, the Investor agrees to pay to the Company within ten (10) business days following the Effective Date, the purchase price per Share equal to the average of the 30-day trailing Volume Weighted Average Price of the Company's Common Stock, as determined by Bloomberg, for the thirty (30) consecutive trading days prior to the Effective Date, less ten percent (10%) as calculated to be \$1.40 per Share for an aggregate purchase price of Thirteen Million dollars (\$13,000,000) (the "Purchase Price").

Within one (1) business days following the date the proceeds are received by Company, the Company shall deliver to the Investor or its designee the shares via DWAC or a stock certificate representing the Shares. The Shares shall be delivered free of restrictive legends and stop transfer instructions.

2. CLOSING

The Closing of the purchase and sale of the Shares shall occur on the date the Purchase Price is received by Company, but in no event later than the date which is ten (10) business days following the Effective Date (the "Closing Date"). On the Closing Date, the Investor shall deliver to the Company the Purchase Price by wire transfer of immediately available funds.

3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY

Except as set forth below, the Company makes no representations or warranties of any nature or kind.

3.1 Organization, Standing and Power. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. The Company has the corporate power to own its properties and to carry on its business as now being conducted and is duly qualified to do business and is in good standing in each jurisdiction in which the failure to be so qualified would have a material adverse effect on the business, assets or condition (financial or otherwise) of the Company and its subsidiaries, taken as a whole.

3.2 Capitalization. The authorized capital stock of the Company consists of 250,000,000 shares of common stock, par value \$0.001 per share, and 5,000,000 shares of preferred stock, par value \$0.001 per share, of which, as of June 16, 2006, there were approximately 179,417,000 shares of common stock and nil shares of preferred stock, issued and outstanding. The Company is not a party to any voting trust agreements or understandings with respect to the voting common stock of the Company. There are no preemptive or similar rights to purchase or otherwise acquire shares of capital stock of the Company pursuant to any provision of law, the Certificate of Incorporation, the bylaws of the Company or any agreement to which the Company is a party.

3.3 Authorization.

3.3.1 The Company has full legal right, power and capacity to enter into, execute, deliver and perform this Agreement and all attendant documents and instruments contemplated hereby.

3.3.2 This Agreement has been duly executed and delivered and constitutes the legal, valid and binding obligation of the Company and is enforceable with respect to the Company in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, priority or other laws or court decisions relating to or affecting generally the enforcement of creditors' rights or affecting generally the availability of equitable remedies.

3.3.3 The execution and delivery of this Agreement by the Company, and the consummation of the transactions contemplated hereby by the Company in accordance with the terms hereof shall not conflict with or result in a breach of, violation of, or default under (or constitute an event that with notice, lapse of time, or both, would constitute a breach or default under), or result in the termination of, or accelerate the performance required by, or result in the creation of any liens or other encumbrances upon any of the properties or assets of the Company under any of the terms, conditions or provisions of the Certificate of Incorporation or Bylaws, any provision of the laws of the State of California or the State of Delaware, or any note, bond, mortgage, indenture, deed of trust, license, lease, credit agreement or other agreement, document, instrument or obligation to which the Company is a party or by which any of its assets or properties are bound.

3.3.4 Neither the execution and delivery of this Agreement by the Company, nor the consummation of the transactions, contemplated hereunder by the Company will violate or conflict with any judgment, order, decree, statute, rule or regulation applicable to the Company or its assets or properties.

3.4 Valid Issuance of Common Stock.

3.4.1 The Shares being purchased by the Investor hereunder, when issued, sold and delivered in accordance with the terms hereof or thereof, for the consideration expressed herein or therein, will be duly and validly issued, fully paid and nonassessable and will be issued in compliance with all applicable federal and state securities laws.

3.4.2 The outstanding shares of Common Stock are all duly and validly authorized and issued, fully paid and nonassessable, and were issued in compliance with all applicable federal and state securities laws.

3.4.3 The Company has full power, right and authority to transfer, convey and sell to the Investors on the Closing Date the Shares and upon consummation of the transactions contemplated by this Agreement, each Investor will have acquired good and marketable title to the Shares purchased by such Investor, free and clear of claims, liens, restrictions on transfer or voting or encumbrances.

3.4.4 The Company has taken the requisite action to cause the Shares to be listed on the Nasdaq Capital Market, and has filed all applications under NASD Rule 2710, if required.

3.5 Litigation. Except as referred to in the SEC Documents, as defined below, the Form S-3, or as disclosed in Schedule 3.5, there are no claims, suits, actions or proceedings pending or, to the knowledge of the Company, threatened against, relating to or affecting the Company or any of its subsidiaries, before any court, governmental department, commission, agency, instrumentality or authority, or any arbitrator that would reasonably be expected, either alone or in the aggregate with all such claims, actions or proceedings, to have a material adverse effect on the Company's business or financial condition or the transactions contemplated hereunder. Except as referred to in the Company's SEC Documents, neither the Company nor any of its subsidiaries is subject to any judgment, decree, injunction, rule or order of any court, governmental department, commission, agency, instrumentality or authority, or any arbitrator which prohibits or restricts the consummation of the transactions contemplated hereby or would have a material adverse effect on the Company's business or financial condition or the transactions contemplated hereunder.

3.6 SEC Documents; the Company's Financial Statements. The Company is a reporting company under the Securities Exchange Act of 1934 (the "Exchange Act"), and files annual and periodic reports (the "SEC Documents") with the Securities and Exchange Commission (the "SEC"). As of their respective filing dates, the SEC Documents complied in all material respects with the requirements of the Securities Exchange Act of 1934, as amended, applicable to the Company and to the knowledge of the Company none of the SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements made therein, in light of the circumstances in which they were made, not misleading, except to the extent corrected by a subsequently filed document with the SEC. The SEC Documents contain an audited consolidated balance sheet of the Company as of the end of the last completed fiscal year (the "Balance Sheet") and the related audited consolidated statements of income and cash flow for the year then ended (collectively, the "Financials"). The Financials have been prepared in accordance with GAAP applied on a basis consistent through the periods indicated and consistent with each other. The Financials present fairly the consolidated financial condition and operating results and cash flows of the Company and its subsidiaries as of the dates and during the periods indicated therein. Since the date of the Balance Sheet and until the date of this Agreement, there has not occurred any material adverse change in the business, assets or condition (financial or otherwise) of the Company and its subsidiaries, taken as a whole, which has not been reflected in the SEC Documents.

3.7 Form S-3. The Company has delivered to each Investor a copy of the Form S-3. The Company represents and warrants that the Form S-3 has been declared effective by the SEC and is not subject to any stop order. The Company is not aware of any event, fact or circumstance, which would cause the Form S-3 to contain a material misstatement or require the filing of an amendment thereto. The Company at the time of the initial filing of the Form S-3 met the SEC's eligibility requirements for use of a Form S-3 in connection with a primary offering. The Company agrees to timely file (i) a Form 8-K disclosing the execution of this Agreement, if and when required, (ii) all periodic reports required to be filed under the Exchange Act in order to keep the S-3 in effect, and (iii) any amendments, if necessary, and deliver to the Investor a copy of any such amendment.

3.8 Disclosure. Neither this Agreement, nor any of the schedules, attachments, or certificates attached to this Agreement or delivered by the Company on the Closing Date, contains any untrue statements of material fact or omits a material fact necessary to make the statements contained herein or therein not misleading. There is no fact which the Company has not disclosed to the Investor, orally or in writing, and of which any of the Company's directors or officers are aware, which could reasonably be anticipated to have a material adverse effect, upon the financial condition, operating results or assets, of the Company. Notwithstanding the foregoing, certain information provided by the Company to the Investor contained statements that are forward-looking, which are covered by the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company.

3.9 No Consents. The execution, delivery and performance by the Company of this Agreement and the offer, issuance and sale of the Shares require no consent of, action by or in respect of, or filing with, any individual or entity, governmental body, agency, or official other than filings that have been made pursuant to applicable state securities laws and post-sale filings pursuant to applicable state and federal securities laws which the Company undertakes to file within the applicable time periods.

3.10 Regulatory Compliance. The Company is not in violation of any applicable law, regulation, judgment, order or consent decree (of any governmental or non-governmental regulatory or self-regulatory agency or any organized exchange, including without limitation, the SEC, any state or local securities or insurance regulatory body, or the Internal Revenue Service), which violation is likely to have a material adverse effect on the Company's business, financial condition, or this transaction.

3.11 Regulatory Proceedings, Investigations and Inquiries. The Company has not been the subject of any material regulatory proceeding, examination, investigation or inquiry (known to the Company), including any pending or threatened regulatory proceeding, investigation or inquiry (known to the Company) (including without limitation any by governmental or non-governmental regulatory or self-regulatory agency or any organized exchange) relating to the Company.

3.12 Registration Statement. The Company's Registration Statement on Form S-3 (the "Registration Statement") was declared effective by the SEC on April 12, 2006. The Registration Statement is effective on the date hereof and the Company has not received notice that the SEC has issued or intends to issue a stop order with respect to such Registration Statement or that the SEC otherwise has suspended or withdrawn the effectiveness of the Registration Statement, either temporarily or permanently, or intends or has threatened in writing to do so. The Registration Statement (including the information or documents incorporated by reference therein), as of the time it was declared effective, and any amendments or supplements thereto, each as of the time of filing, did not contain any untrue statement of material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading. In addition, the Company hereby agrees to file with the SEC, as required, no later than two business days from the Effective Date, either an amendment or a prospectus supplement in accordance with Rule 424(b)(2) of the Securities Act. The Registration Statement registers the issuance of the Shares to the Investor and, when issued to the Investor, the Shares shall be freely tradeable by the Investor.

3.13 Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq Capital Market continued listing requirements. There are no proceedings pending or, to the Company's knowledge, threatened against the Company relating to the continued listing of the Common Stock on the Nasdaq Capital Market and the Company has not received any currently effective notice of, nor to the Company's knowledge is there any basis for, the delisting of the Common Stock from the Nasdaq Capital Market.

4. REPRESENTATIONS AND WARRANTIES OF THE INVESTOR

The Investor hereby represents and warrants to the Company the following:

4.1 Authority. Investor has full legal right, power and capacity to enter into, execute, deliver and perform this Agreement and all attendant documents and instruments contemplated hereby. This Agreement has been duly executed and delivered and constitutes the legal, valid and binding obligation of Investor and is enforceable with respect to Investor in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, priority or other laws or court decisions relating to or affecting generally the enforcement of creditors' rights or affecting generally the availability of equitable remedies.

4.2 No Violation of Agreements. Neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereunder by Investor will violate or conflict with any judgment, order, decree, statute, rule or regulation applicable to Investor or its assets or properties.

4.3 Disclosure of Information. Subject in part to the truth and accuracy of the representations and warranties of the Company, the Investor believes that it has received all the information that it considers necessary or appropriate for deciding whether to purchase the Shares. The Investor further represents that it has had an opportunity to review the SEC Documents and the Form S-3, and had sufficient opportunity to ask questions and receive answers from the Company and its directors and officers regarding the terms and conditions of the offering of the Shares and the business and operations of the Company. The foregoing, however, does not limit or modify the representations and warranties of the Company in Section 3 of this Agreement or the right of the Investor to rely thereon.

4.4 Compliance with Law; Any sale or other transaction by the Investor in securities of the Company shall be made in compliance with all applicable laws and regulations.

5. CONDITIONS PRECEDENT TO OBLIGATIONS OF THE COMPANY

The obligations of the Company to consummate this Agreement shall be subject to the satisfaction of each of the conditions set forth below, any or all of which may be waived by the Company in whole or in part without prior notice; provided, however, that no such waiver of a condition shall constitute a waiver by the Company of any other condition or of any of the Company's rights or remedies, at law or in equity, if the Investor shall be in default or breach of any of its representations, warranties or agreements under this Agreement:

5.1 Purchase Price. Investor shall deliver the Purchase Price on the date specified in Section 1.2.

5.2 Accuracy of Representations and Warranties. The representations and warranties of the Investor contained in this Agreement shall be accurate and complete on and as of the date hereof and the Closing Date with the same effect as though such representations and warranties had been made on or as of such date.

5.3 Performance of Agreements. Each and all of the conditions precedent and agreements of the Investor subject to satisfaction on or before the Closing Date pursuant to the terms of this Agreement shall have been performed or satisfied.

6. CONDITIONS PRECEDENT TO OBLIGATIONS OF INVESTOR

The obligations of the Investor to consummate the transactions contemplated by this Agreement shall be subject to the satisfaction of each of the conditions set forth below, any or all of which may be waived by each Investor in whole or in part without prior notice; provided, however, that no such waiver of a condition shall constitute a waiver by such Investor of any other condition or of any of the Investor's rights or remedies, at law or in equity, if the Company shall be in default or breach of any of its representations, warranties or agreements under this Agreement:

6.1 Accuracy of Representations and Warranties. The representations and warranties of the Company contained in this Agreement shall be accurate and complete on and as of the date hereof and the Closing Date with the same effect as though such representations and warranties had been made on or as of such date.

6.2 Performance of Agreements. Each and all of the conditions precedent and agreements of the Company subject to satisfaction on or before the Closing Date pursuant to the terms of this Agreement shall have been performed or satisfied.

6.3 No Adverse Events. Between the date hereof and the Closing Date, neither the business, assets or condition, financial or otherwise, of the Company taken as a whole shall have been materially adversely affected in any manner.

7. INDEMNIFICATION

7.1 To the extent permitted by law, the Company will indemnify and hold harmless, the Investor, the directors and officers, if any, of the Investor, and each person, if any, who controls the Investor within the meaning of the Securities Act or the Exchange Act (each, an "Indemnified Person"), against any losses, claims, damages, liabilities or expenses (joint or several) incurred (collectively, "Claims") to which any of them may become subject under the Securities Act, the Exchange Act or otherwise, insofar as such Claims (or actions or proceedings, whether commenced in respect thereof) arise out of or are based upon: (i) any untrue statement or untrue statement of a material fact contained in the Registration Statement or any post-effective amendment thereof or the omission or omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii) any untrue statement or untrue statement of a material fact contained in the final prospectus (as amended or supplemented, if the Company files any amendment thereof or supplement thereto with the SEC) or the omission or omission to state therein any material fact necessary to make the statements made therein, in the light of the circumstances under which the statements therein were made, not misleading or (iii) any violation or violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation under the Securities Act, the Exchange Act or any state securities law (the matters in the foregoing clauses (i) through (iii) being collectively referred to as "Violations"). The Company shall reimburse the Investor, promptly as such expenses are incurred and are due and payable, for any reasonable legal fees or other reasonable expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section 7 shall not (i) apply to any Claims arising out of or based upon a Violation which occurs in reliance upon and in conformity with information furnished in writing to the Company by or on behalf of any Indemnified Person expressly for use in connection with the preparation of the Registration Statement or any such amendment thereof or supplement thereto, (ii) be available to the extent such Claim is based on a failure of the Investor to deliver or cause to be delivered the prospectus made available by the Company; or (iii) apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld. The Investor will indemnify the Company, its officers, directors and agents (including legal counsel) (each an "Indemnified Person") against any claims arising out of or based upon a Violation which occurs in reliance upon and in conformity with information furnished in writing to the Company, by or on behalf of the Investor, expressly for use in connection with the preparation of the Registration Statement, subject to such limitations and conditions set forth in this Section 7. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person or Indemnified Party, and shall survive the sale of the Shares by the Subscriber.

7.2 Promptly after receipt by an Indemnified Person under this Section of notice of the commencement of any action (including any governmental action), such Indemnified Person shall, if a Claim in respect thereof is to be made against any indemnifying party under this Section, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof with counsel mutually satisfactory to the indemnifying party and the Indemnified Person, as the case may be; provided, however, that an Indemnified Person shall have the right to retain its own counsel with the reasonable fees and expenses to be paid by the indemnifying party, if, in the reasonable opinion of counsel retained by the indemnifying party, the representation by such counsel of the Indemnified Person and the indemnifying party would be inappropriate due to actual or potential differing interests between such Indemnified Person and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not relieve such indemnifying party of any liability to the Indemnified Person under this Section except to the extent that the indemnifying party is prejudiced in its ability to defend such action. The indemnification required by this Section shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as such expense, loss, damage or liability is incurred and is due and payable.

7.3 To the extent any indemnification by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect to any amounts for which it would otherwise be liable under Section 7 to the fullest extent permitted by law.

8. COVENANTS AND MISCELLANEOUS.

8.1 Subject to Section 8.15 below, the Company agrees that for a period of one hundred and eighty (180) calendar days following the Effective Date, it shall not file a shelf registration statement with the SEC pursuant to Rule 415 of the Securities Act.

8.2 (a) Subject to Section 8.15 below, during the period from the Closing Date until January 2, 2007 (the "Restricted Period"), the Company hereby grants to the Investor the right of first refusal (the "Right of First Refusal") to purchase the New Securities (as defined below) that the Company may, from time to time and in one or more transactions, propose to sell and issue.

(b) The term "New Securities" means any offering by the Company of any Common Stock or securities convertible into Common Stock and shall specifically include common stock issued for services provided to the Company, but exclude common stock issued in strategic licensing transactions where the Company is either in-licensing new technologies or out-licensing of technologies.

(c) In the event that the Company proposes to undertake an issuance of New Common Stock during the Restricted Period, the Company shall give written notice thereof (an "Offering Notice"). The Offering Notice shall specify, in detail, the general terms and conditions upon which the Company proposes to issue the same.

(d) The Investor shall have the right, for a period (the "Exercise Period") expiring at 5:00 PM (Eastern Time) on the third (3rd) Trading Day following the date of the Offering Notice, to purchase the New Securities for the price and on the general terms and conditions specified in the Offering Notice. Such exercise shall be effected by the Investor giving written notice of such exercise (the "Exercise Notice") to the Company as hereinafter provided. If the Exercise Notice is not received by the Company within the prescribed timeframe, then Company shall have the right to consummate the transaction within the following ten (10) Trading Days. Once the Exercise Notice is received by the Company, Investor agrees to complete the transaction within the following ten (10) Trading Days. Notwithstanding the foregoing, in the event Investor provides Exercise Notice to Company and Investor does not close the transaction within the prescribed ten (10) Trading Days, then the foregoing covenant shall immediately terminate.

8.3 Expenses, Commissions and Taxes. Each party shall bear and pay its own expenses, including legal, accounting and other professional fees, and taxes incurred in connection with the transactions referred to in this Agreement. The party responsible under applicable law shall bear and pay in their entirety all other taxes and registration and transfer fees, if any, payable by reason of the sale and conveyance of the Shares.

8.4 Entire Agreement; Modifications; Waiver. This Agreement, together with the related agreements or certificates referenced herein, constitutes the final, exclusive and complete understanding of the parties with respect to the subject matter hereof and supersedes any and all prior understandings and discussions with respect thereto. No variation or modification of this Agreement and no waiver of any provision or condition hereof, or granting of any consent contemplated hereby, shall be valid unless in writing and signed by the party against whom enforcement of any such variation, modification, waiver or consent is sought.

8.5 Further Assurances. The parties hereto shall use their best efforts, and shall cooperate with one another, to secure all necessary consents, approvals, authorizations, exemptions and waivers from third parties as shall be required in order to consummate the transactions contemplated hereby, and shall otherwise use their best efforts to cause such transactions to be consummated in accordance with the terms and conditions hereof. At any time or from time to time after the Closing Date, each party hereto, shall execute and deliver any further instruments or documents and take all such further action as such requesting party may reasonably request in order to consummate and document the transactions contemplated hereby.

8.6 Captions. The captions in this Agreement are for convenience only and shall not be considered a part of or affect the constructing or interpretation of any provision of this Agreement.

8.7 Section References. Unless otherwise noted, all section references herein are to sections of this Agreement.

8.8 Counterparts. This Agreement may be executed in any number of counterparts, including electronically transmitted counterparts, each of which when so executed shall constitute an original copy hereof, but all of which together shall constitute one agreement.

8.9 Successors and Assigns. Neither party shall have the right to assign this Agreement.

8.10 Parties in Interest. Nothing in this Agreement, whether express or implied, is intended to confer any rights or remedies under or by reason of this Agreement on any persons other than the parties to it and their respective successors and assigns, nor is anything in this Agreement intended to relieve or discharge the obligation or liability of any third persons to any party to this Agreement, nor shall any provision give any third persons any right of subrogation or action over against any party to this Agreement.

8.11 Notices. All notices, requests, demands and other communications hereunder (“Notices”) shall be in writing and shall be deemed to have been duly given if delivered by hand or by registered or certified mail or upon fax notice with confirmation of receipt, as follows:

If to Investor: c/o DOUBLE U MASTER FUND L. P.
Harbour House
Waterfront Drive
P.O. Box 972
Road Town, Tortola
British Virgin Islands
Attention: Carl Jacobsohn
Telephone: (284) 494-4770
Facsimile: (284) 494-4771

with copy to: Krieger & Prager LLP
39 Broadway, Suite 920
New York, NY 10006
Attention: Samuel Krieger
Telephone: (212) 363-2900
Facsimile: (212) 363-2999

If to the Company: Peregrine Pharmaceutical, Inc.
14272 Franklin Avenue, Suite 100
Tustin, California 92780
Attn.: Steve King
Facsimile: (714) 838-5817

with copy to: Snell & Wilmer LLP
Mr. Mark Ziebell
600 Anton Blvd, Suite 1400
Costa Mesa, CA 92626
Telephone: (714) 427-7000
Facsimile: (714) 427-7799

or to such other address as any party may have furnished to the others in writing in accordance herewith, except that notices of change of address shall only be effective upon receipt. All Notices shall be deemed received on the date of delivery or, if mailed, on the date appearing on the return receipt therefor.

8.12 Law Governing. This Agreement shall be governed by, and construed and enforced in accordance with the laws of the State of California, without regard to its choice-of-laws or conflicts-of-law rules.

8.13 Survival. The representations and warranties contained in this Agreement shall survive the Closing Date indefinitely.

8.14 Subject to Section 8.15 below, the Company covenants and agrees that during the period (the “New Transaction Period”) from the Effective Date and continuing through and including the Final Lock-up Date (as defined below), it will not, without the prior written consent of the Investor in each instance, enter into any subsequent or further offer or sale of Common Stock or securities convertible into and/or other rights exercisable for the issuance of Common Stock (including common stock issued for services provided to the Company, but excluding common stock issued in strategic licensing transactions where the Company is either in-licensing new technologies or out-licensing of technologies) at a price or possible price below \$2.50 (collectively, “New Common Stock”) to or with any third party (any such offer or sale of New Common Stock, a “New Transaction”). The term “Final Lock-up Date” means January 2, 2007.

8.15 In the event that the closing price of the Company’s common stock shall equal or exceed \$2.50 for a period of fifteen (15) consecutive trading days (the “Target Price Period”) at any time commencing 30 Business Days following the Effective Date and prior to the stated ending dates in Sections 8.1, 8.2 and 8.14 above, then the covenants, prohibitions, limitations and/or restrictions contained in such Sections shall automatically terminate upon the day immediately following the conclusion of the Target Price Period, and the provisions shall no longer be of any force and effect.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed, all as of date first above written.

“The Company”
Peregrine Pharmaceuticals, Inc.,
a Delaware corporation

By: /s/ Paul Lytle

Name: Paul Lytle

Title: CFO

“Investor”
DOUBLE U MASTER FUND LP

By: /s/ Authorized Signer

Name: Navigator Management Ltd.

Title: Authorized Signer